Nabil specialises in IP and regulatory advice for clients ranging from start-ups to global players, with a particular focus on the life sciences and other technology-rich sectors.

Nabil provides pragmatic, commercially-minded advice with a focus on intellectual property strategy and regulatory compliance. In addition to advice on the identification, protection, commercialisation and enforcement of IP rights, Nabil supports clients with commercial contracts, due diligence, and regulatory compliance.

Prior to training as a solicitor, Nabil worked in early phase pharmaceutical R&D for AstraZeneca and chaired the Physical Organic Chemistry Group of the Royal Society of Chemistry.

显示完整简历 隐藏完整简历

最新新闻和观点

酒店与休闲

Global pharma groups Eli Lilly and AbbVie withdraw from UK’s branded medicines voluntary scheme

2023年1月18日
Briefing

作者 Nabil Asaad, PhD 以及 Lauren Mounteney

点击此处了解更多
computing
Interface - Quantum computing - the next really big thing

Using quantum computing in life sciences

Nabil Asaad looks at the potential for quantum computing to revolutionise life sciences.

2022年3月14日

作者 Nabil Asaad, PhD

2 / 4 观点

点击此处了解更多
酒店与休闲

Advising IP Group on option exercise to accelerate development of first-in-class gene therapy for patients with cystic fibrosis

2021年10月29日

作者 Colin McCall 以及 Nabil Asaad, PhD

点击此处了解更多
酒店与休闲

CJEU referral on violations of data protection law on the basis of competition law and on the interpretation of the concept of health data

2023年3月24日
Briefing

作者 Dr. Daniel Tietjen 以及 Dr. David Klein, LL.M. (Univ. of Washington), CIPP/E

点击此处了解更多

与我会面: